Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals | COVID-19 Impact Analysis

Global Insulin Market $45.4 Billion by 2027

The global market for insulin anticipated to attain $45.4 billion by 2027, expanding at a CAGR of 4.8% over the forecast period, drive by increasing prevalence of diabetic population, launch of highly potent and cost-effective drugs, and rich pipeline of candidates by major pharmaceutical companies.

  • Diabetes is a chronic disease that occurs either when the pancreas does not produce enough insulin or when the body cannot effectively use the insulin produced by the pancreas. Insulin is the ultimate care for people with diabetes.
    • According to Centers for Disease Control and Prevention (CDC), the diabetes pandemic is fueled by growing rates of obesity.
      • The poor diagnosis rates, lack of access to optimal treatment and poor glycemic control remain global problems.
Global Human Insulin Market

According to the WHOGlobal report on diabetes“, globally, an estimated 422 million adults were living with diabetes in 2014, compared to 108 million in 1980. There were about 347 million people were suffering from diabetes in 2013, and it is expected to become the seventh leading cause of death in the world by 2030.

  • The global prevalence (age-standardized) of diabetes has nearly doubled since 1980, rising from 4.7% to 8.5% in the adult population.
    • This reflects an increase in associated risk factors such as being overweight or obese.
  • Over the past decade, diabetes prevalence has risen faster in low- and middle-income countries than in high-income countries.
    • The lack of access to affordable insulin remains a key impediment to successful treatment and results in needless complications and premature deaths.
  • Insulin and oral hypoglycemic agents are reported as generally available in only a minority of low-income countries.
    • Moreover, essential medicines critical to gaining control of diabetes, such as agents to lower blood pressure and lipid levels, are frequently unavailable in low- and middle-income countries.
    • Policy and programme interventions are needed to improve equitable access.

Human Insulin and Insulin Analogs are available for insulin replacement therapy. There are three main groups of insulins: Fast-acting, Intermediate-acting and Long-acting insulin.

  • Fast-acting insulin includes rapid acting insulin analogs – Apidra (Glulisine), Humalog (Lispro), Novolog (Aspart), and regular (R) or short-acting human insulin includes Humulin R, Novolin R (human recombinant).
  • Intermediate-acting insulin includes Neutral Protamine Hagedorn (NPH) human insulin – Humulin N, Novolin N (Isophane) and pre-mixed insulin.
  • Mixed or combination insulins includes shorter acting insulin combined with a longer acting insulin such as Humulin 70/30, Novolin 70/30, Novolog 70/30, Humulin 50/50, and Humalog mix 75/25. Long-acting insulin includes long acting insulin analogs Lantus (Glargine), Levemir (Detemir), Basaglar (Glargine).
    • Affordability of insulin has become a major issue for patients with diabetes in the United States.
      • Synthetic human insulin, once the mainstay of treatment, is much less expensive but is now prescribed less frequently.
      • The price of insulin, particularly insulin analogues, has increased substantially over the past 2 decades.

The global insulin market report estimates the market size ($million 2017 to 2027), market volume (thousand mega units), market share, growth trends and forecast (CAGR% 2021 to 2027).

The global market for insulin segmented by source type (human, recombinant), mode of action (short-acting insulin, rapid-acting or fast-acting insulin, long-acting insulin, intermediate-acting insulin, premix insulin), pipeline analysis [rapid-acting insulin – Afrezza, NN1218 (FIAsp); long-acting insulin – IDegLira (Xultophy), LY2605541(novel basal insulin analog), LY2963016 (long acting basal insulin), MK-1293 (sustained release insulin analog), U-300 (Toujeo)] and geography.

  • Insulin treatment is one of the major steps in a patient’s regime against type 1 diabetes. Animal insulin dominated the market in the initial years, but advances in science and technology helped in the introduction various methods of insulin production.
    • Presently, human insulin is produced from genetically engineered bacteria with high purity and biocompatibility compared to animal insulin.
      • After the introduction of modern insulin products, various drawbacks of animal and human insulin were overcome such as hypoglycemia, lack of flexibility, weight gain and adherence.

The global market for insulin research report is further divided by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

In addition, the global market for insulin report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major competitors operating in the global market for insulin and included in this report are Eli Lilly and Company, Novo Nordisk A/A, Sanofi S.A., Fosun Pharma (Shanghai Fosun Pharmaceutical Co., Ltd.) and Thermalin Diabetes, LLC.

  • Source
    • Human Insulin
    • Recombinant / Modern Insulin
  • Mode of Action
    • Short-Acting Insulin
    • Rapid-Acting Insulin (Fast-Acting)
    • Long-Acting Insulin
    • Intermediate-Acting Insulin
    • Premix Insulin
  • Pipeline Analysis
    • Rapid-Acting Insulin
      • Afrezza
      • NN1218 (FIAsp)
    • Long-Acting Insulin
      • IDegLira (Xultophy)
      • LY2605541(Novel Basal Insulin Analog)
      • LY2963016 (Long Acting Basal Insulin)
      • MK-1293 (Sustained Release Insulin Analog)
      • U-300 (Toujeo)
  • Company Profiles
    • Eli Lilly and Company
    • Novo Nordisk A/S
    • Sanofi S.A.
    • Fosun Pharma (Shanghai Fosun Pharmaceutical Co., Ltd.)
    • Thermalin Diabetes, LLC

To request Table of Contents and Sample Pages of this report visit:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 463-5840
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: [email protected]